Erschienen in:
01.03.2022 | Correspondence
Another trial for the TARGET trial
verfasst von:
Mohammad H. Alshaer, Charles A. Peloquin
Erschienen in:
Intensive Care Medicine
|
Ausgabe 6/2022
Einloggen, um Zugang zu erhalten
Excerpt
We commend the authors for publishing the TARGET trial [
1] which highlights therapeutic drug monitoring (TDM) in critically ill patients with severe sepsis or septic shock. These patients received piperacillin/tazobactam as continuous infusion. The investigators carefully tracked the piperacillin concentrations every day for up to 10 days. The primary trial outcome compared the mean Sequential Organ Failure Assessment (SOFA) score from day 1 to 10 between the TDM and non-TDM arms. We would like to highlight a few points that may improve the clarity of the results. …